The use of ustekinumab in a patient with severe psoriasis and positive HBV serology
AUTOR(ES)
Steglich, Raquel Bissacotti, Meneghello, Luana Pizarro, Carvalho, André Vicente Esteves de, Cheinquer, Hugo, Muller, Fernanda Melo, Reginatto, Flávia Pereira
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2014-07
RESUMO
Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the world's population. Immunobiological medications are prescribed for certain patients with severe forms of psoriasis, however, these drugs increase the risk of reactivation of viral diseases such as hepatitis B. We report the case of a patient with severe psoriasis with positive serology for the Hepatitis B virus, who received ustekinumab (a human monoclonal antibody against interleukin 12 and 23). In this patient, the use of ustekinumab did not reactivate the Hepatitis B virus. Given the high prevalence of chronic viral infections in patients who are candidates for biologic therapy, as well as the potential for reactivate chronic viral illness, randomized controlled studies are needed to assess the risks and benefits of such therapy in these populations.
Documentos Relacionados
- Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis
- Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease
- Pemphigus foliaceus with pustular presentation in a patient with psoriasis
- Profile of blood donations with a positive serology in Southern Brazil
- HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors